Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02180074 · ClinicalTrials.gov registry record
Measurement of Distinct Biological Pools of Hydrogen Sulfide in Women With Cardiovascular Disease
A clinical trial, sponsored by Louisiana State University Health Sciences Center Shreveport.
- Completed
- Registry status
- 137
- Enrollment target
NCT02180074: Completed study, sponsored by Louisiana State University Health Sciences Center Shreveport.
NCT02180074 is a clinical trial that has completed, run by Louisiana State University Health Sciences Center Shreveport. The registered enrollment target is 137 participants. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT02180074 has completed, sponsored by Louisiana State University Health Sciences Center Shreveport.
- COMPLETED
- Registry status
- 137 participants
- Enrollment target
Study Summary
Cardiovascular disease which includes coronary artery disease and peripheral artery disease remains the leading cause of death among women in the United States. The impact of cardiovascular in women was not recognized by clinicians for a long time. It is now evident that, women suffer the consequences of cardiovascular at rates at least as high as those observed in men but there are still major gaps in our understanding this disease in women. Hydrogen sulfide (H2S), a gaseous mediator plays an important role in the cardiovascular system. Research has demonstrated it's critical role in animal ischemia reperfusion models. Hydrogen sulfide exists in distinct biological pools in blood. Recently, the Kevil lab has pioneered the development of new analytical techniques for accurate measurement of all biological pools of H2S. By measuring these distinct pools of H2S in women with and without cardiovascular disease the investigators hope to further understanding of role of H2S in pathophysiology of cardiovascular disease. This research will help to assess the ability of H2S and its distinct biological pools to potentially be a diagnostic marker or a therapeutic target for cardiovascular disease.
Primary Outcome
Unit of Measure: nMol
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 137 participants |
| Start Date | 2013-09 |
| Est. Completion | 2017-05-07 |
What the finished NCT02180074 record still lists
NCT02180074 is an observational study that tracks outcomes without assigning an intervention. The registered 137 participants enrollment target is mid-sized for trials with a published cap.
The record links to 0 conditions, and to 0 interventions.
NCT02180074 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT02180074 about?
NCT02180074 is a clinical study titled "Measurement of Distinct Biological Pools of Hydrogen Sulfide in Women With Cardiovascular Disease". Cardiovascular disease which includes coronary artery disease and peripheral artery disease remains the leading cause of death among women in the United States. The impact of cardiovascular in women was not recognized by clinicians for a long time. It is now evident that, women suffer the consequenc...
What is the current status of trial NCT02180074?
This trial is currently completed. The enrollment target is 137 participants. The study started on 2013-09. Estimated completion is 2017-05-07.
Who is sponsoring clinical trial NCT02180074?
This trial is sponsored by Louisiana State University Health Sciences Center Shreveport, which has 40 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT05091424 · 137 participants · Phase 1
A Study Evaluating the Safety, Efficacy, and Pharmacokinetics of Mosunetuzumab and a Combined Regimen of Mosunetuzumab and Venetoclax in Participants With Relapsed or Refractory Chronic Lymphocytic Leukemia
- NCT05655182 · 137 participants · Phase 1
A Study of BLB-201 RSV Vaccine in Infants and Children
- NCT06571669 · 137 participants · NA
BOOM-IBD2 Pivotal Clinical Trial
- NCT06644768 · 137 participants · Phase 1
A Study of Valemetostat Tosylate Plus Pembrolizumab Versus Pembrolizumab Alone in First-Line NSCLC Without Actionable Genomic Alterations
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia